| Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling N Li, Y Xi, HN Tinsley, E Gurpinar, BD Gary, B Zhu, Y Li, X Chen, ... Molecular cancer therapeutics 12 (9), 1848-1859, 2013 | 132 | 2013 |
| Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice D Li, N Li, YF Zhang, H Fu, M Feng, D Schneider, L Su, X Wu, J Zhou, ... Gastroenterology 158 (8), 2250-2265. e20, 2020 | 119 | 2020 |
| Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma N Li, H Fu, SM Hewitt, DS Dimitrov, M Ho Proceedings of the National Academy of Sciences 114 (32), E6623-E6631, 2017 | 116 | 2017 |
| Glypicans as cancer therapeutic targets N Li, W Gao, YF Zhang, M Ho Trends in cancer 4 (11), 741-754, 2018 | 109 | 2018 |
| Colon tumor cell growth–inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition HN Tinsley, BD Gary, J Thaiparambil, N Li, W Lu, Y Li, YY Maxuitenko, ... Cancer Prevention Research 3 (10), 1303-1313, 2010 | 89 | 2010 |
| A frizzled‐like cysteine‐rich domain in Glypican‐3 mediates Wnt binding and regulates hepatocellular carcinoma tumor growth in mice N Li, L Wei, X Liu, H Bai, Y Ye, D Li, N Li, U Baxa, Q Wang, L Lv, Y Chen, ... Hepatology 70 (4), 1231-1245, 2019 | 81 | 2019 |
| A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity JD Whitt, N Li, HN Tinsley, X Chen, W Zhang, Y Li, BD Gary, AB Keeton, ... Cancer prevention research 5 (6), 822-833, 2012 | 79 | 2012 |
| Glypican‐3‐specific antibody drug conjugates targeting hepatocellular carcinoma Y Fu, DJ Urban, RR Nani, YF Zhang, N Li, H Fu, H Shah, AP Gorka, ... Hepatology 70 (2), 563-576, 2019 | 73 | 2019 |
| Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity N Li, K Lee, Y Xi, B Zhu, BD Gary, V Ramírez-Alcántara, E Gurpinar, ... Oncogene 34 (12), 1499-1509, 2015 | 73 | 2015 |
| β-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG K Lee, AS Lindsey, N Li, B Gary, J Andrews, AB Keeton, GA Piazza Oncotarget 7 (5), 5353, 2016 | 61 | 2016 |
| The role of glypicans in cancer progression and therapy N Li, MR Spetz, M Ho Journal of Histochemistry & Cytochemistry 68 (12), 841-862, 2020 | 56 | 2020 |
| A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy E Gurpinar, WE Grizzle, JJ Shacka, BJ Mader, N Li, NA Piazza, S Russo, ... Molecular cancer therapeutics 12 (5), 663-674, 2013 | 50 | 2013 |
| Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma L Sun, F Gao, Z Gao, L Ao, N Li, S Ma, M Jia, N Li, P Lu, B Sun, M Ho, ... Journal for Immunotherapy of Cancer 9 (4), 2021 | 47 | 2021 |
| Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10 N Li, X Chen, B Zhu, V Ramírez-Alcántara, JC Canzoneri, K Lee, S Sigler, ... Oncotarget 6 (29), 27403, 2015 | 44 | 2015 |
| Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling B Zhu, A Lindsey, N Li, K Lee, V Ramirez-Alcantara, JC Canzoneri, ... Oncotarget 8 (41), 69264, 2017 | 30 | 2017 |
| CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice N Li, MB Torres, MR Spetz, R Wang, L Peng, M Tian, CM Dower, ... Cell Reports Medicine 2 (6), 2021 | 26 | 2021 |
| Novel non-cyclooxygenase inhibitory derivatives of naproxen for colorectal cancer chemoprevention T Aboul-Fadl, SS Al-Hamad, K Lee, N Li, BD Gary, AB Keeton, GA Piazza, ... Medicinal Chemistry Research 23, 4177-4188, 2014 | 23 | 2014 |
| Development of highly effective anti-mesothelin hYP218 chimeric antigen receptor T cells with increased tumor infiltration and persistence for treating solid tumors S Tomar, J Zhang, M Khanal, J Hong, A Venugopalan, Q Jiang, ... Molecular cancer therapeutics 21 (7), 1195-1206, 2022 | 21 | 2022 |
| Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3 N Li, MR Spetz, D Li, M Ho Pharmacology & therapeutics 223, 107892, 2021 | 10 | 2021 |
| GPC1-targeted immunotoxins inhibit pancreatic tumor growth in mice via depletion of short-lived GPC1 and downregulation of Wnt signaling J Pan, N Li, A Renn, H Zhu, L Chen, M Shen, MD Hall, M Qian, I Pastan, ... Molecular cancer therapeutics 21 (6), 960-973, 2022 | 5 | 2022 |
